The clinical significance of soluble human leukocyte antitgen class-I, ICTP, and RANKL molecules in multiple myeloma patients
- 29 February 2008
- journal article
- Published by Elsevier in Human Immunology
- Vol. 69 (2) , 79-87
- https://doi.org/10.1016/j.humimm.2008.01.006
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survivalAnnals of Hematology, 2005
- Increased serum concentrations of soluble HLA-class I antigens in hepatitis C virus related mixed cryoglobulinaemiaAnnals of the Rheumatic Diseases, 2000
- Increased Soluble Serum HLA Class I Antigens in Patients with LymphomaHuman Immunology, 1997
- Elevated serum level of soluble HLA class I antigens in patients with systemic lupus erythematosusArthritis & Rheumatism, 1996
- Soluble HLA Class I and Beta‐2‐Microglobulin Plasma Concentrations during Interferon Treatment of Chronic Myelogenous LeukemiaVox Sanguinis, 1994
- C-reactive protein and beta-2 microglobulin produce a simple and powerful myeloma staging systemBlood, 1992
- Serum thymidine kinase in monoclonal gammopathies. A prospective studyCancer, 1992
- SOLUBLE HLA CLASS I CONCENTRATIONS AND GVHD AFTER ALLOGENEIC MARROW TRANSPLANTATIONTransplantation, 1989
- A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survivalCancer, 1975